Hypertension JNC VI: Risk Stratification and Treatment
* Lifestyle modification should be adjunctive therapy for all patients recommended for pharmacologic therapy.
† For patients with multiple risk factors, clinicians should consider drugs as initial therapy plus lifestyle modifications.
‡ For those with heart failure, renal insufficiency, or diabetes.
TOD/CCD = target organ disease/clinical cardiovascular disease.
JNC VI. November 1997:chapter 2. NIH publication 98-4080.
High-normal Lifestyle Lifestyle Drug therapy‡ (130-139/85-89) modification modification
Stage 1 Lifestyle Lifestyle Drug therapy (140-159/90-99) modification modification† (up to 12 mo) (up to 6 mo)
Stages 2 and 3 Drug therapy Drug therapy Drug therapy (_160/ _100)
Risk Group C
Risk Group B (TOD/CCD and/or
Blood Pressure Risk Group A (At least 1 risk factor, diabetes, with or
Stages (No risk factors; not including diabetes; without other (mm Hg) no TOD/CCD) no TOD/CCD) risk factors)
HTN Remains under-diagnosed & under treated
| Previous slide | Next slide | Back to first slide | View graphic version |